Kuebler, Peter J.
Mehrotra, Megha L.
Shaw, Brian I.
Leadabrand, Kaitlyn S.
Milush, Jeffrey M.
York, Vanessa A.
Grant, Robert M.
Kallas, Esper G.
Nixon, Douglas F.
Total Authors: 10
 Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 - USA
 Gladstone Inst, Gladstone Inst Virol & Immunol, San Francisco, CA - USA
 Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 - USA
 Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo - Brazil
 George Washington Univ, Dept microbiol Immunol & Trop Med, Washington, DC - USA
Total Affiliations: 5
Journal of Infectious Diseases;
FEB 15 2016.
Web of Science Citations:
We leveraged data from the Preexposure Prophylaxis Initiative (iPrEx), a global trial of preexposure chemoprophylaxis against human immunodeficiency virus type 1 (HIV-1) infection, to compare T-cell activation between those who remained negative for HIV-1 and those who became infected during the trial. The frequency of CD38(+)HLA-DR(+)CD8(+)T cells was greater in those who seroconverted, relative to the frequency in those who remained uninfected (1.30% vs 0.82%, respectively; P = .005). This translated to an odds ratio of 4.26 (95% confidence interval, 1.54-11.78) for the association between CD8(+)T-cell activation and infection with HIV-1. T-cell activation may be a biomarker for elevated HIV-1 infection risk. (AU)